12:00 AM
 | 
Apr 02, 2007
 |  BioCentury  |  Finance

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 3/30 cls
Alexza (ALXA) JMP Securities Charles Duncan Price target Market outperform 29% $12.86
Duncan raised his target to $19 from $15 after ALXA reported positive Phase IIb data for AZ-001 to treat migraine and Phase IIa data for AZ-004 to treat acute agitation in schizophrenia (see B13). He said the results validate ALXA's drug delivery platform.
AtheroGenics (AGIX) Fortis Geraldine O'Keeffe Discontinued NA -29% $2.81
O'Keeffe dropped coverage after AGIX reported...

Read the full 522 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >